Market Intelligence, Clinical Progress, and High-Purity Reagents for Cerebral Cavernous Malformations Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCM2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCM2 Recombinant Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for PPI assays. |
View CCM2 Products |
| Gene Delivery | CCM2 Promise-ORF / Lentivirus Full-length ORF for stable expression and rescue assays in endothelial cells. |
View CCM2 Products |
| Benchmark Ab | Anti-CCM2 Recombinant Antibody Sequence-verified positive control for expression and localization studies. |
View CCM2 Products |
| Validator | CCM2 siRNA Set For knockdown verification to simulate loss-of-function phenotypes. |
View CCM2 Products |
| Related Target A | CCM1 (KRIT1) Essential binding partner in the CCM signalosome complex regulating endothelial junctions. |
View CCM1 Products |
| Related Target B | CCM3 (PDCD10) Critical adapter protein forming the heterotrimeric complex with CCM1 and CCM2. |
View CCM3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting the CCM1-CCM2-CCM3 Complex | Sequence-verified recombinant proteins with strict purity controls (>95% by SDS-PAGE) to ensure stoichiometric accuracy. |
| Simulating Loss-of-Function in Endothelial Cells | High-efficiency siRNA sets and high-titer Lentivirus for reliable knockdown and rescue validation. |
| Lack of Controls | Sequence-defined recombinant antibodies included for robust benchmark detection. |
| False Positives | Validated knockdown reagents included for target-specific validation. |
Live CCM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCM2 therapeutics is intensifying, with major players shifting focus from traditional symptom management to gene therapies and targeted small molecules. As first-generation therapies targeting downstream signaling (such as ROCK inhibitors) reach the clinic, the next wave of R&D is targeting direct protein-protein interaction (PPI) stabilization and genetic rescue strategies using advanced delivery vectors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lentivirus) | Academic Medical Centers, Biotech Startups | Cerebral Cavernous Malformations (CCM) | Expression & Functional Rescue Assay (Need high-titer Lentivirus & sequence-verified ORF) |
| Small Molecule (ROCK/MEKK3 Inhibitors) | Recursion Pharmaceuticals, BioAxone | Familial CCM, Vascular Malformations | Downstream Pathway Readout (Need CCM2 knock-down validation via siRNA) |
| Protein/Peptide Therapeutics (PPI Stabilizers) | Preclinical Discovery Groups | Hemorrhagic Stroke Prevention | Complex Assembly Validation (Need high-purity CCM1, CCM2, and CCM3 proteins) |